{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:34:01Z","timestamp":1740130441276,"version":"3.37.3"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2018,6,13]],"date-time":"2018-06-13T00:00:00Z","timestamp":1528848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/about_us\/legal\/notices"}],"funder":[{"name":"National Cancer Center Research and Development Fund","award":["TIN2012-32180"],"award-info":[{"award-number":["TIN2012-32180"]}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["TIN2012-32180"],"award-info":[{"award-number":["TIN2012-32180"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8,1]]},"DOI":"10.1093\/jjco\/hyy085","type":"journal-article","created":{"date-parts":[[2018,5,30]],"date-time":"2018-05-30T07:19:23Z","timestamp":1527664763000},"page":"777-780","source":"Crossref","is-referenced-by-count":2,"title":["Phase III study of watchful waiting vs. rituximab as first-line treatment in advanced stage follicular lymphoma with low tumour burden (JCOG1411, FLORA study)"],"prefix":"10.1093","volume":"48","author":[{"given":"Kenichi","family":"Miyamoto","sequence":"first","affiliation":[{"name":"Japan Clinical Oncology Group Data Center\/Operations Office, National Cancer Center, Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Fukuhara","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Cancer Center Hospital, Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"Shibata","sequence":"additional","affiliation":[{"name":"Japan Clinical Oncology Group Data Center\/Operations Office, National Cancer Center, Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Japan Clinical Oncology Group Data Center\/Operations Office, National Cancer Center, Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Ishizawa","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cell Therapy, Yamagata University Faculty of Medicine, Yamagata"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiro","family":"Tsukasaki","sequence":"additional","affiliation":[{"name":"Department of Hematology, International Medical Center, Saitama Medical University, Saitama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Nagai","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Lymphoma Study Group of the Japan Clinical Oncology Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,6,13]]},"reference":[{"year":"2016","author":"Foundation for Promotion of Cancer Research","key":"key\n\t\t\t\t20180724061906_hyy085C1"},{"author":"NCCN","key":"key\n\t\t\t\t20180724061906_hyy085C2"},{"key":"key\n\t\t\t\t20180724061906_hyy085C3","first-page":"42","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180724061906_hyy085C4","first-page":"101","article-title":"Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation","volume":"97","author":"Colombat","year":"2001","journal-title":"Blood"},{"key":"key\n\t\t\t\t20180724061906_hyy085C5","first-page":"2017","article-title":"Influence of the watch and wait strategy on clinical outcomes of patients with follicular lymphoma in the rituximab era","volume":"95","author":"Yuda","year":"2016","journal-title":"Ann Hematol"},{"key":"key\n\t\t\t\t20180724061906_hyy085C6","first-page":"424","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t20180724061906_hyy085C7","first-page":"3096","article-title":"Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: Eastern Cooperative Oncology Group Protocol E4402","volume":"32","author":"Kahl","year":"2014","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180724061906_hyy085C8","first-page":"1110","article-title":"Comparsion in low-tumor burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon a: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180724061906_hyy085C9","first-page":"163","article-title":"Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint","volume":"38","author":"Schoenfeld","year":"1982","journal-title":"Biometrics"},{"key":"key\n\t\t\t\t20180724061906_hyy085C10","first-page":"659","article-title":"Discrete sequential boundaries for clinical trials","volume":"70","author":"Lan","year":"1983","journal-title":"Biometrika"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/48\/8\/777\/25205613\/hyy085.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,7,24]],"date-time":"2018-07-24T06:19:24Z","timestamp":1532413164000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/48\/8\/777\/5037012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,13]]},"references-count":10,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,6,13]]},"published-print":{"date-parts":[[2018,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyy085","relation":{},"ISSN":["1465-3621"],"issn-type":[{"type":"electronic","value":"1465-3621"}],"subject":[],"published-other":{"date-parts":[[2018,8]]},"published":{"date-parts":[[2018,6,13]]}}}